CARGO Therapeutics, Inc. (CRGX)
| Market Cap | 953.90M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -64.14M |
| Shares Out | 41.21M |
| EPS (ttm) | -1.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 462,614 |
| Open | 22.94 |
| Previous Close | 22.72 |
| Day's Range | 21.65 - 29.01 |
| 52-Week Range | 13.14 - 29.01 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 28.33 (+22.38%) |
| Earnings Date | Feb 21, 2024 |
About CRGX
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, In... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for CRGX stock is "Strong Buy." The 12-month stock price forecast is $28.33, which is an increase of 22.38% from the latest price.
News
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell th...
Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold ...
CARGO Therapeutics Announces Pricing of Initial Public Offering
CARGO Therapeutics, Inc., a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies...
Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 each
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $...
CARGO Therapeutics IPO Registration Document (S-1)
CARGO Therapeutics has filed to go public with an IPO on the NASDAQ.